Eculizumab
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Atypical Hemolytic Uremic
Conditions
Atypical Hemolytic Uremic
Trial Timeline
Jul 14, 2023 → May 7, 2025
NCT ID
NCT05876351About Eculizumab
Eculizumab is a phase 3 stage product being developed by AstraZeneca for Atypical Hemolytic Uremic. The current trial status is completed. This product is registered under clinical trial identifier NCT05876351. Target conditions include Atypical Hemolytic Uremic.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06724809 | Phase 3 | Active |
| NCT05876351 | Phase 3 | Completed |
| NCT05886244 | Phase 3 | Completed |
Competing Products
18 competing products in Atypical Hemolytic Uremic
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crovalimab | Chugai Pharmaceutical | Phase 3 | 77 |
| Crovalimab | Chugai Pharmaceutical | Phase 3 | 77 |
| Duloxetine | Eli Lilly | Approved | 85 |
| Teriparatide 20 mcg | Eli Lilly | Phase 3 | 77 |
| Baricitinib | Eli Lilly | Pre-clinical | 23 |
| Ravulizumab | AstraZeneca | Pre-clinical | 23 |
| Iptacopan | Novartis | Phase 3 | 77 |
| Iptcaopan 200 mg | Novartis | Phase 3 | 77 |
| Iptacopan | Novartis | Phase 3 | 77 |
| Ropeginterferon Alfa-2B | PharmaEssentia | Phase 2 | 51 |
| CCX168 | Amgen | Phase 2 | 51 |
| Tazemetostat + Nivolumab + Ipilimumab | Bristol Myers Squibb | Phase 1/2 | 40 |
| Cemdisiran | Alnylam Pharmaceuticals | Phase 2 | 49 |
| cemdisiran + Placebos | Alnylam Pharmaceuticals | Phase 2 | 49 |
| Axatilimab + Azacitidine | Incyte | Phase 1/2 | 38 |
| Gemcitabine + Paxalisib | Pacific Biosciences | Phase 2 | 44 |
| Apatinib Mesylate | Brain Biotech | Pre-clinical | 15 |
| azurin-derived cell-penetrating peptide p28 | Brain Biotech | Phase 1 | 25 |